Have we given up on a cure for ovarian cancer? - Narod

Current Oncology

Commentary

Have we given up on a cure for ovarian cancer?

---

A Countercurrents Series^a
S.A. Narod , MD ^*
* Women’s College Research Institute, Women’s College Hospital, Toronto, ON.


doi: http://dx.doi.org/10.3747/co.22.2517

In December 2014, on the force Web site, executive director Sue Friedman, heralded a game-changing holiday gift for people with BRCA mutations: “Today is a landmark for the hboc [hereditary breast and ovarian cancer] community”1. In an accompanying article 2, Lisa Rezende wrote about the U.S. Food and Drug Administration ( fda ) decision to approve olaparib for the treatment of recurrent ovarian cancer in women with a BRCA1 or BRCA2 mutation:.......

REFERENCES

1. Friedman S. A Game-Changing Holiday Gift for People with BRCA Mutations [blog post]. Tampa, FL: Facing Our Risk of Cancer Empowered (force); 2014. [Available at: http://www.facingourrisk.org/get-involved/HBOC-community/BRCAHBOC-blogs/FORCE/uncategorized/a-game-changing-holiday-gift-for-people-with-brca-mutations/; cited 17 April 2015]

2. Rezende L. FDA Approves the First PARP Inhibitor for Treatment of Ovarian Cancer in BRCA Mutation Carriers [Web page]. Tampa, FL: Facing Our Risk of Cancer Empowered (force); 2014. [Available at: http://www.facingourrisk.org/research-clinical-trials/research-findings/lynparza.php; cited 17 April 2015]

3. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 2014;15:852–61.
    

4. Oza AM, Cibula D, Benzaquen AO, et al. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol 2015;16:87–97.
  

5. McLaughlin JR, Rosen B, Moody J, et al. Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2. J Natl Cancer Inst 2013;105:141–8.
    

6. Venook AP, Tabernero J. Progression-free survival: helpful biomarker or clinically meaningless end point? J Clin Oncol 2015;33:4–6.
  

7. Secord AA, Barnett JC, Ledermann JA, Peterson BL, Myers ER, Havrilesky LJ. Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target parp inhibitor use in platinum-sensitive recurrent ovarian cancer. Int J Gynecol Cancer 2013;23:846–52.
    

8. Quested T. AZ lines up second Cambridge blockbuster drug. Business Weekly 2014; October 27:. [Available online at: http://www.businessweekly.co.uk/news/biomedtech/17728-az-lines-second-cambridge-blockbuster-drug; cited 27 April 2015]

9. Myriad Receives FDA Approval of BRACAnalysis cdx as Companion Diagnostic for Lynparza (olaparib) in Ovarian Cancer Patients [press release]. Salt Lake City, UT: Myriad Genetics; 19 December 2014. [Available online at: http://investor.myriad.com/releasedetail.cfm?releaseid=888523; cited 17 April 2015]

10. Byrski T, Dent R, Blecharz P, et al. Results of a phase ii open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer. Breast Cancer Res 2012;14:R110.
  

11. Tutt A, Ellis P, Kilburn L, et al. The tnt trial: a randomized phase iii trial of carboplatin (c) compared with docetaxel (d) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (cruk/07/012) [abstract S3-01]. In: Program and abstracts of the 2014 San Antonio Breast Cancer Symposium; San Antonio, TX, U.S.A.; 9–13 December 2014. [Available online at: http://www.abstracts2view.com/sabcs14/view.php?nu=SABCS13L_789; cited 17 April 2015]

12. Burger RA, Brady MF, Bookman MA, et al. on behalf of the Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011;365:2473–83.
    

13. Perren TJ, Swart AM, Pfisterer J, et al. on behalf of the icon 7 investigators. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011;365:2484–96.
    

14. Nixon RM. Annual Message to the Congress on the State of the Union. 22 January 1971. In: Peters G, Woolley JT. The American Presidency Project [Web site]. Santa Barbara, CA: The American Presidency Project; n.d. [Available at: http://www.presidency.ucsb.edu/ws/?pid=3110; cited 17 April 2015]

15. Rosen B, Laframboise S, Ferguson S, et al. The impacts of neoadjuvant chemotherapy and of debulking surgery on survival from advanced ovarian cancer. Gynecol Oncol 2014;134:462–7.